PURPOSE This study aimed to validate whether the recently-proposed prognostic grading system, initial brain metastasis velocity (iBMV), is applicable to breast cancer patients receiving stereotactic radiosurgery (SRS). We focused particularly on whether this grading system is useful for patients with all molecular types, i.e., positive versus negative for EsR, PgR and HER2. METHODS AND MATERIALS This was an institutional review board-approved, retrospective cohort study using our database, prospectively accumulated at three gamma knife institutes, during the 20-year-period since 1998. We excluded patients for whom the day of primary cancer diagnosis was not available, had synchronous presentation, lacked information regarding molecular types, and/or had received pre-SRS radiotherapy and/or surgery. We ultimately studied 511 patients categorized into two classes by iBMV scores, i.e., < 2.00 and ≥ 2.00. RESULTS The median iBMV score for the entire cohort was 0.97 (IQR 0.39-2.84). Median survival time (MST) in patients with iBMV < 2.00, 15.9 (95% CI 13.0-18.6, IQR 7.5-35.5) months, was significantly longer than that in patients with iBMV ≥ 2.00, 8.2 (95% CI 6.8-9.9, IQR 3.9-19.4) months (HR 1.582, 95% CI: 1.308-1.915, p < 0.0001). The same results were obtained in patients with EsR (-), PgR (-), HER2 (+) and HER2 (-) cancers, while MSTs did not differ significantly between iBMV < 2.00 vs ≥ 2.00 in patients with EsR (+) and PgR (+) cancers. CONCLUSIONS This system was clearly shown to be applicable to breast cancer patients with SRS-treated BMs. However, this system is not applicable to patients with hormone receptor (+) breast cancer.

中文翻译：

---

三机构研究初始脑转移速度对接受立体定向放射外科手术的乳腺癌脑转移患者的适用性。

目的该研究旨在验证最近提出的预后分级系统，即初始脑转移速度（iBMV）是否适用于接受立体定向放射外科手术（SRS）的乳腺癌患者。我们特别关注这种分级系统是否适用于所有分子类型的患者，即EsR，PgR和HER2阳性或阴性。方法和材料这是一项经过机构审查委员会批准的回顾性队列研究，使用了我们的数据库，该研究自1998年以来的20年期间在三个伽玛刀研究机构中进行了前瞻性积累。我们排除了那些没有被诊断为原发癌日的患者可用，同步显示，缺乏有关分子类型的信息和/或已接受SRS之前的放疗和/或手术。我们最终研究了511名根据iBMV评分分为两类的患者，即<2.00和≥2.00。结果整个队列的中位iBMV得分为0.97（IQR 0.39-2.84）。iBMV <2.00，15.9（95％CI 13.0-18.6，IQR 7.5-35.5）月的患者的中位生存时间（MST）明显长于iBMV≥2.00，8.2（95％CI 6.8-9.9， IQR 3.9-19.4）月（HR 1.582，95％CI：1.308-1.915，p <0.0001）。在EsR（-），PgR（-），HER2（+）和HER2（-）癌症患者中获得了相同的结果，而iBMV <2.00 vs≥2.00的EsR（+）和EsR（+）患者的MST差异不显着PgR（+）癌症。结论该系统已明确显示适用于SRS治疗的BMs的乳腺癌患者。然而，